Tsur2019 - Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm Lab
About lab
This is a simple mathematical model describing the interactions of an advanced melanoma tumor with both the immune system and the immunotherapy drug, pembrolizumab. It can be used to explore immune response dynamics and compare pathway-level behavior across conditions.
Runtime
Duration10
Comms Step1
Runs
Total0
Completed0
Failed0
Metadata
Packagetsur2019-predicting-response-to-pembrolizumab-in-metastatic-mela
Created2026-05-15
Updated2026-05-15
immunologysbmlbiomodels_ebifaithfulcuratedvisualisation
Manifest
{
"io": {
"inputs": [
{
"name": "initial_unresolved_prediction_observable_1",
"label": "Initial Unresolved Prediction Observable 1",
"units": "native source value",
"default": 1,
"maps_to": "immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model.initial_unresolved_prediction_observable_1",
"description": "Initial Unresolved Prediction Observable 1. Sets the initial value of bundled SBML species `A_pc`."
},
{
"name": "initial_unresolved_prediction_observable_2",
"label": "Initial Unresolved Prediction Observable 2",
"units": "native source value",
"default": 1,
"maps_to": "immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model.initial_unresolved_prediction_observable_2",
"description": "Initial Unresolved Prediction Observable 2. Sets the initial value of bundled SBML species `T_il`."
},
{
"name": "initial_unresolved_prediction_observable_3",
"label": "Initial Unresolved Prediction Observable 3",
"units": "native source value",
"default": 50,
"maps_to": "immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model.initial_unresolved_prediction_observable_3",
"description": "Initial Unresolved Prediction Observable 3. Sets the initial value of bundled SBML species `M_el`."
}
],
"outputs": [
{
"name": "unresolved_prediction_observable_1",
"maps_to": "immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model.unresolved_prediction_observable_1"
},
{
"name": "unresolved_prediction_observable_2",
"maps_to": "immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model.unresolved_prediction_observable_2"
},
{
"name": "unresolved_prediction_observable_3",
"maps_to": "immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model.unresolved_prediction_observable_3"
},
{
"name": "state",
"maps_to": "immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model.state"
},
{
"name": "summary",
"maps_to": "immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model.summary"
},
{
"name": "species_labels",
"maps_to": "immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model.species_labels"
}
]
},
"title": "Tsur2019 - Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm Lab",
"models": [
{
"path": "owned/models/immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model",
"alias": "immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model",
"provenance": {
"owned_path": "owned/models/immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model"
}
},
{
"path": "owned/models/visualisation",
"alias": "visualisation",
"provenance": {
"owned_path": "owned/models/visualisation"
}
}
],
"wiring": [
{
"to": [
"visualisation.immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model_state"
],
"from": "immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model.state"
},
{
"to": [
"visualisation.immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model_summary"
],
"from": "immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model.summary"
},
{
"to": [
"visualisation.immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model_species_labels"
],
"from": "immunology_sbml_tsur2019_predicting_response_to_pembrolizumab_in_model1911150001_model.species_labels"
}
],
"runtime": {
"duration": 10,
"initial_inputs": {},
"communication_step": 1
},
"description": "This is a simple mathematical model describing the interactions of an advanced melanoma tumor with both the immune system and the immunotherapy drug, pembrolizumab. It can be used to explore immune response dynamics and compare pathway-level behavior across conditions.",
"schema_version": "2.0"
}Sign in to start your own run. Public-lab history stays visible here.
Select a run from History to view its results.